Imperial College London

ProfessorRobertWilkinson

Faculty of MedicineDepartment of Infectious Disease

Professor in Infectious Diseases
 
 
 
//

Contact

 

r.j.wilkinson Website

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@unpublished{Davies:2022:10.1101/2022.01.12.22269148,
author = {Davies, M-A and Kassanjee, R and Rosseau, P and Morden, E and Johnson, L and Solomon, W and Hsiao, N-Y and Hussey, H and Meintjes, G and Paleker, M and Jacobs, T and Raubenheimer, P and Heekes, A and Dane, P and Bam, J-L and Smith, M and Preiser, W and Pienaar, D and Mendelson, M and Naude, J and Schrueder, N and Mnguni, A and Roux, SL and Murie, K and Prozesky, H and Mahomed, H and Rossouw, L and Wasserman, S and Maughan, D and Boloko, L and Smith, B and Taljaard, J and Symons, G and Ntusi, N and Parker, A and Wolter, N and Jassat, W and Cohen, C and Lessells, R and Wilkinson, RJ and Arendse, J and Kariem, S and Moodley, M and Vallabhjee, K and Wolmarans, M and Cloete, K and Boulle, A},
doi = {10.1101/2022.01.12.22269148},
publisher = {Cold Spring Harbor Laboratory},
title = {Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.},
url = {http://dx.doi.org/10.1101/2022.01.12.22269148},
year = {2022}
}

RIS format (EndNote, RefMan)

TY  - UNPB
AB - OBJECTIVES: We aimed to compare COVID-19 outcomes in the Omicron-driven fourth wave with prior waves in the Western Cape, the contribution of undiagnosed prior infection to differences in outcomes in a context of high seroprevalence due to prior infection, and whether protection against severe disease conferred by prior infection and/or vaccination was maintained. METHODS: In this cohort study, we included public sector patients aged ≥20 years with a laboratory confirmed COVID-19 diagnosis between 14 November-11 December 2021 (wave four) and equivalent prior wave periods. We compared the risk between waves of the following outcomes using Cox regression: death, severe hospitalization or death and any hospitalization or death (all ≤14 days after diagnosis) adjusted for age, sex, comorbidities, geography, vaccination and prior infection. RESULTS: We included 5,144 patients from wave four and 11,609 from prior waves. Risk of all outcomes was lower in wave four compared to the Delta-driven wave three (adjusted Hazard Ratio (aHR) [95% confidence interval (CI)] for death 0.27 [0.19; 0.38]. Risk reduction was lower when adjusting for vaccination and prior diagnosed infection (aHR:0.41, 95% CI: 0.29; 0.59) and reduced further when accounting for unascertained prior infections (aHR: 0.72). Vaccine protection was maintained in wave four (aHR for outcome of death: 0.24; 95% CI: 0.10; 0.58). CONCLUSIONS: In the Omicron-driven wave, severe COVID-19 outcomes were reduced mostly due to protection conferred by prior infection and/or vaccination, but intrinsically reduced virulence may account for an approximately 25% reduced risk of severe hospitalization or death compared to Delta.
AU - Davies,M-A
AU - Kassanjee,R
AU - Rosseau,P
AU - Morden,E
AU - Johnson,L
AU - Solomon,W
AU - Hsiao,N-Y
AU - Hussey,H
AU - Meintjes,G
AU - Paleker,M
AU - Jacobs,T
AU - Raubenheimer,P
AU - Heekes,A
AU - Dane,P
AU - Bam,J-L
AU - Smith,M
AU - Preiser,W
AU - Pienaar,D
AU - Mendelson,M
AU - Naude,J
AU - Schrueder,N
AU - Mnguni,A
AU - Roux,SL
AU - Murie,K
AU - Prozesky,H
AU - Mahomed,H
AU - Rossouw,L
AU - Wasserman,S
AU - Maughan,D
AU - Boloko,L
AU - Smith,B
AU - Taljaard,J
AU - Symons,G
AU - Ntusi,N
AU - Parker,A
AU - Wolter,N
AU - Jassat,W
AU - Cohen,C
AU - Lessells,R
AU - Wilkinson,RJ
AU - Arendse,J
AU - Kariem,S
AU - Moodley,M
AU - Vallabhjee,K
AU - Wolmarans,M
AU - Cloete,K
AU - Boulle,A
DO - 10.1101/2022.01.12.22269148
PB - Cold Spring Harbor Laboratory
PY - 2022///
TI - Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.
UR - http://dx.doi.org/10.1101/2022.01.12.22269148
UR - https://www.medrxiv.org/content/10.1101/2022.01.12.22269148v1
UR - http://hdl.handle.net/10044/1/96526
ER -